Skip to main content
. 2023 Apr 11;15(4):1211. doi: 10.3390/pharmaceutics15041211
AKI Acute kidney injury
ALI Acute lung injury
ARDS Acute Respiratory Distress Syndrome
AUC Area under the curve
AZM Azithromycin
CSTH Critical temperature of solution in hexane
CST Critical temperature of solution
DED Dry eye disease
F4H5 Perfluorobutylpentane
F6H8 Perfluorohexyloctane
F6H8-cEM Perfluorohexyloctane-containing emulsions
F6H8S5 perfluorohexyloctane/polydimethylsiloxane
F6H10 Perfluorohexyldecane
HBO Hyperbaric hyperoxygenation
H2O Water
H&E Hematoxylin and eosin (staining)
mAb Monoclonal antibodies
MCT Medium-Chain Triglyceride
MGD Myoboma gland dysfunction
MMAD Mass Median Aerodynamic Diameter
mPas Millipascal
MRT Magnetic resonance tomography
19F-MRI 19F magnetic resonance imaging
NBO Normobaric hyperoxygenation
NMR Nuclear magnetic resonance
19F-NMR 19F nuclear magnetic resonance
PET Positron emission tomography
PFCs Perfluorcarbons
PFCL Perfluorocarbon liquids
PFD Perfluorodecaline
PFO Perfluorooctane
PFOB Perfluoroctylbromide
PLV Partial liquid ventilation
PTFE Polytetrafluoroethylene
PVR Proliferative vitreoretinopathy
RES Reticuloendothelial system
SFAs Semifluorinated alkanes
S75 Lecithin
SH Sodium hyaluronate
TLV Total liquid ventilation
VEGF Vascular endothelial growth factor